Clinical trial NCT01783314 - References

Hepatic Fibrosis — Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

Citation(s)

•   Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB
  Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology. 2006 May;239(2):425-37.
•   Albanis E, Friedman SL
  Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis. 2001 May;5(2):315-34, v-vi. Review.
•   Asbach P, Klatt D, Hamhaber U, Braun J, Somasundaram R, Hamm B, Sack I
  Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med. 2008 Aug;60(2):373-9. doi: 10.1002/mrm.21636.
•   Bedossa P, Dargère D, Paradis V
  Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec;38(6):1449-57.
•   Berg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, Mazariegos GV
  Liver and intestine transplantation in the United States 1998-2007. Am J Transplant. 2009 Apr;9(4 Pt 2):907-31. doi: 10.1111/j.1600-6143.2009.02567.x.
•   Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ
  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8.
•   Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, Shih TT
  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012 Jan;22(1):171-80. doi: 10.1007/s00330-011-2249-5. Epub 2011 Aug 31.
•   Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B
  Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006 Oct;13(10):652-8.
•   d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO
  Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics. 2006 Mar-Apr;26(2):621-32.
•   Friedman SL
  Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000 Jan 28;275(4):2247-50. Review.
•   Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA, Taouli B
  Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. Radiology. 2008 Mar;246(3):926-34. doi: 10.1148/radiol.2463070077. Epub 2008 Jan 14.
•   Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, Wolf KJ, Weinmann HJ, Lange L
  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995 Jun;195(3):785-92.
•   Ji H, Ros PR
  Magnetic resonance imaging. Liver-specific contrast agents. Clin Liver Dis. 2002 Feb;6(1):73-90. Review.
•   Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, Miyazawa T, Narumi Y, Monden M, Nakamura H
  Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997 Jul-Aug;7(4):683-8.
•   Kovalev VA, Kruggel F, Gertz HJ, von Cramon DY
  Three-dimensional texture analysis of MRI brain datasets. IEEE Trans Med Imaging. 2001 May;20(5):424-33.
•   Laking GR, West C, Buckley DL, Matthews J, Price PM
  Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol. 2006 May;58(2):95-113. Epub 2006 Jan 4. Review.
•   Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ
  Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986 Mar 8;1(8480):523-5.
•   Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C
  Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009 Dec;72(3):217-38. doi: 10.1016/j.critrevonc.2008.07.012. Epub 2008 Aug 29. Review.
•   Mendoza J, Gómez-Domínguez E, Moreno-Otero R
  [Transient elastography (Fibroscan), a new non-invasive method to evaluate hepatic fibrosis]. Med Clin (Barc). 2006 Feb 18;126(6):220-2. Review. Spanish.
•   Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A, Espacio R
  Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat. 2009 Apr;16(4):249-58. doi: 10.1111/j.1365-2893.2009.01088.x. Epub 2009 Feb 7. Review.
•   Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, Matsuda M, Fujii H, Enomoto N, Araki T
  Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011 Oct;29(8):1047-52. doi: 10.1016/j.mri.2011.05.007. Epub 2011 Jul 19.
•   Murakami T, Kim T, Gotoh M, Hasuike Y, Kato N, Miyazawa T, Monden M, Nakamura H
  Experimental hepatic dysfunction: evaluation by MR imaging with Gd-EOB-DTPA. Acad Radiol. 1998 Apr;5 Suppl 1:S80-2.
•   Murtagh J, Foerster V
  Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis. Issues Emerg Health Technol. 2006 Sep;(90):1-4.
•   Olsson R, Hägerstrand I, Broomé U, Danielsson A, Järnerot G, Lööf L, Prytz H, Rydén BO, Wallerstedt S
  Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol. 1995 Oct;48(10):933-5.
•   Pagliaro L, Rinaldi F, Craxì A, Di Piazza S, Filippazzo G, Gatto G, Genova G, Magrin S, Maringhini A, Orsini S, Palazzo U, Spinello M, Vinci M
  Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci. 1983 Jan;28(1):39-43.
•   Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER
  The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996 Jun;43(6):568-71.
•   Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER
  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8.
•   Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, Solá R, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M
  Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology. 2008 Mar;47(3):810-6.
•   Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, Kim YS, Kang DS
  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol. 2004 Oct-Dec;5(4):231-9.
•   Schuster DP
  The opportunities and challenges of developing imaging biomarkers to study lung function and disease. Am J Respir Crit Care Med. 2007 Aug 1;176(3):224-30. Epub 2007 May 3. Review.
•   Segers J, Le Duc G, Laumonier C, Troprès I, Elst LV, Muller RN
  Evaluation of Gd-EOB-DTPA uptake in a perfused and isolated mouse liver model: correlation between magnetic resonance imaging and monochromatic quantitative computed tomography. Invest Radiol. 2005 Sep;40(9):574-82.
•   Shimizu J, Dono K, Gotoh M, Hasuike Y, Kim T, Murakami T, Sakon M, Umeshita K, Nagano H, Nakamori S, Kato N, Miyazawa T, Nakamura H, Monden M
  Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci. 1999 Jul;44(7):1330-7.
•   Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA, Tobias H
  Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol. 2007 Oct;189(4):799-806.
•   Tsuda N, Okada M, Murakami T
  New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol. 2010 Jan;73(1):137-42. doi: 10.1016/j.ejrad.2008.09.036. Epub 2008 Nov 20.
•   Tsuda N, Okada M, Murakami T
  Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol. 2007 Apr;42(4):242-7.
•   Zeremski M, Talal AH
  Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol. 2005 Jul;43(1):2-5. Review.

Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

Details for clinical trial NCT01783314